Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.
2.

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Volles MJ, Lansbury PT Jr.

Biochemistry. 2003 Jul 8;42(26):7871-8. Review.

PMID:
12834338
3.
4.

Synucleins and their relationship to Parkinson's disease.

von Bohlen Und Halbach O.

Cell Tissue Res. 2004 Oct;318(1):163-74. Epub 2004 Jul 24. Review.

PMID:
15503152
5.
6.

The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Wakabayashi K, Tanji K, Mori F, Takahashi H.

Neuropathology. 2007 Oct;27(5):494-506. Review.

PMID:
18018486
7.
8.

Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein.

Masliah E, Hashimoto M.

Neurotoxicology. 2002 Oct;23(4-5):461-8. Review.

PMID:
12428718
9.

Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H.

Neuropharmacology. 2003 Jul;45(1):14-44. Review.

PMID:
12814657
10.

Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.

El-Agnaf OM, Irvine GB.

J Struct Biol. 2000 Jun;130(2-3):300-9. Review.

PMID:
10940234
11.
12.

Alpha-synuclein aggregation.

Bodles AM, Irvine GB.

Protein Pept Lett. 2004 Jun;11(3):271-9. Review.

PMID:
15182228
13.

[Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].

Wakabayashi K.

Rinsho Shinkeigaku. 2008 Nov;48(11):981-3. Review. Japanese.

PMID:
19198138
14.

Caught in the act: alpha-synuclein is the culprit in Parkinson's disease.

Eriksen JL, Dawson TM, Dickson DW, Petrucelli L.

Neuron. 2003 Oct 30;40(3):453-6. Review.

15.

Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.

Meredith SC.

Ann N Y Acad Sci. 2005 Dec;1066:181-221. Review.

PMID:
16533927
16.

Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.

Hegde ML, Jagannatha Rao KS.

Arch Biochem Biophys. 2003 Oct 15;418(2):169-78. Review.

PMID:
14522588
17.

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT.

J Mol Neurosci. 2004;23(1-2):23-34. Review.

PMID:
15126689
18.

Alpha-synuclein: normal function and role in neurodegenerative diseases.

Norris EH, Giasson BI, Lee VM.

Curr Top Dev Biol. 2004;60:17-54. Review.

PMID:
15094295
19.

The synuclein family.

Lavedan C.

Genome Res. 1998 Sep;8(9):871-80. Review.

20.

Supplemental Content

Support Center